Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of Fenretinide in Healthy Volunteers
NCT06181760Phase 1Completed
- Sponsor
- Island Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fenretinide in dengue fever (4 arms), sponsored by Island Pharmaceuticals. Primary endpoints: Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions, Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions and 2 more. Started Nov 2023; status: completed.
02
Drugs
fenretinide
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06181760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181760.